Monsanto's Weedkiller Payout Slashed to $400 Million From $2.25 Billion
By Ben Glickman
A court has reduced the amount Bayer-owned Monsanto must pay in a recent case linked to Roundup by about 82%, or nearly $1.9 billion, easing the latest cost in the company's drawn-out legal battle related to the weedkiller.
Monsanto will now be required to pay $350 million in punitive damages and just over $50 million in compensatory damages, according to court documents released on Tuesday. The company was originally ordered earlier this year to pay $2.25 billion in damages by a Philadelphia court.
Monsanto said on Tuesday it would seek an appeal in the Superior Court of Pennsylvania and that it disagreed with the court's ruling on the liability verdict.
The jury in January sided with the plaintiff, who alleged that he developed cancer from exposure to Roundup, a weedkiller owned by Monsanto. Bayer has maintained that Roundup and its main ingredient, glyphosate, is safe to use, pointing to opinions from regulators that determine the compound isn't a risk cancer risk.
Monsanto said Tuesday that it stood behind Roundup and "the overwhelming weight of scientific research and assessments by leading health regulators and scientists."
Bayer has been plagued by a number of lawsuits related to Roundup since its $63 billion deal to acquire Monsanto in 2018. The company lost two cases late last year with damages totalling over $2 billion.
The reduced payout comes as the pharmaceutical and agricultural conglomerate is looking to slash its debt, address ongoing lawsuits and revamp its pharmaceutical drug pipeline. The company in March said it wasn't pursuing a split into separate units, an option preferred by some investors.
Monsanto said that it had favorable outcomes in 14 of the last 20 trials, including the last four, and has resolved the majority of claims.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 04, 2024 18:44 ET (22:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued